Hikma Pharmaceuticals Stock News

LONDON, Sept. 10, 2026 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma, Group) announces that regulatory submissions for its epinephrine nasal spray, being developed for the emergency treatment of allergic reactions (anaphylaxis), have been accepted for review by regulators in the United States, Europe, and the UK.

Panmure Liberum has raised its target price for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) from 1,600p to 1,900p, saying the drugmaker's strong first-half results support further upside in its shares. The broker said Hikma's recent interim results were reassuring, with the only surprises coming on the upside and beats reported across the business.

Jefferies has raised its price target on Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) to 2,025p from 1,870p, pointing to the expanding contract manufacturing business as the source of the upgrade. The 'buy' rating is unchanged, with the new target implying 24% upside from Tuesday's share price of 1,633p (flat).

Citi has raised its estimates for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) following stronger-than-expected half-year results, arguing that the FTSE 100 drugmaker's valuation discount is no longer justified. Ephrem Ravi reiterated a buy rating and set a new price target of £18.70.

Deutsche Bank has raised its target price for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) to 2,050p from 1,950p, reiterating its 'buy' rating on the FTSE 100 drugmaker. Kane Slutzkin said Hikma delivered a substantial beat at the half-year stage, driven primarily by the branded division, yet left full-year guidance largely unchanged.

Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares rose 10% to 1,721p after first-half results came in ahead of expectations on profits, with both Peel Hunt and Stifel keeping buy ratings. The scale of the beat is the story.

Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trump's proposed tariffs on generic drugs because of their extensive US manufacturing operations, according to Citi. The US president this week announced plans to impose a 100% tariff on imported generic medicines from August 2028, rising to 200% a year later.